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tlbm. We examined the impact of thrombolytie therapy 
and tbe prognosis of patifxlts witb Mm-Q wave mycwzardtal infare- 
tioninara5domizedphe&wonhlledtrialkriownastheLate 
Assessment of Tbrombolytk ElrKaey (LATE) study. 
lla&mdPatientswltbnon-QwaveaseolapglPdwitbQ 
wavemyomdallrtfardonintheerabefore~bolytietberapy 
weretradh&&thou$ittobavea~rateofFeinfarrtioa 
anddeathk&weeabospitaldhlmrgeandlyearsnehthatthe 
overaUpwgno&foroateomeat1yearwassimilartnbtuv 
groaps. 
M~TBestudyputlentsbegoem~twitlIeitbf!r 
t-esombllt tissoe-tyae plassdnogen activator (r&PA) or matdk 
i~placebo,6to24Laflortheonsetd~~n.Postl1ac 
mmlyslsofmortalltyaud-wascarliedontbyeDmpar- 
blglt-PAaa8pbJC&OlUWUiOOSSObSetSOfpatieatSbssedoSt8e 
preaen~~(ECG)mldtlte~tionoftbe 
ECGwitbrespMtothedev&pmentofQwaves 
lfesuk Among 5,711 pnrMpan& 4759 bad a eoehra3ed 
w@$alei++=t@ ;w L=J asbavinga 
-am--@f 
hwtmentaas+ment,allpatientswithnon-Qwavewrsu.sQwave 
inlardioa~aleaerl-yeru~~(W39b~17.1%,p= 
@.@Ol)amIasimilarl-pearrrMar&mrate(&69bvs.7.9%,p= 
@.7). of tbe 4759 patients wltb -myoeardipl 
2$73presentedwithSTsegmentekvationorboedk~ 
bhn&528wtthSFdepreshandl,25SdtttneitberSfekv&m 
nor depressioa No averall benefit from H-PA versus pkebo with 
nqeettomortatityrateat1ycarwassealamongpatients 
presen~rritssfoleratioe(21~rs.ztn4p=tt5[Iwkpona 
tadeteet2$%mlativedWemxe]).PaWt.swlthSf~wlm 
were treated wltb r&PA versus ptaeebo <3 b after lmqital 
adl&s&ntuIdaiaror~rateat1~(15~v&1969b, 
p=o~)tsaedldthocletrratse~Ja(17~Vkrs.UA46,p= 
@.@55).Patifslts~~ipithltgvitl,sf~.2mm 
beaeotfnxu- uitbrt-PAwithqto 
rate(2&l%vk3t9L&,p=tMw. 
Treatment of acute myocardial infarction with thromholytic 
agents improves prognosis when administered to patients with 
ST elevation or bundle branch block up to 12 h from tbe onset 
of chest pain (1). In an animal model of myocardial infarction 
with sudden coromuy oczhkon, near complete mywar&l 
necrosis was demo&rated hy 3 h (2), sagest@ that be&t 
observedinhumansforupto12his~rektedto 
continued perfwsion to the infarct zone. Patients presenting 
with a non-Q wave i&r&on have evidence of amtinued 
perfusion to the infarct zone becauszof subocclusive tbrombus 
or collateral eirarktion (3.4). 
Morereuxtiy,non-Qwavemyocardialinfar&wocwriq 
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reasons for this paradox are unclear; however, the number of 
patients with ST depression and confirmed myocardial infarc- 
tion in these trials was small (11) or unknown (9,10), and the 
mortality rate in patients with ST depression and confirmed 
i&r&m is high (12). The aims of the present post hoc 
anafysis of Late Assessment of Thrombolytic Efficacy (LATE) 
study (13) were 1) to assess the impact of thromboiytic therapy 
on prognosis in a broad cross section of patients who develop 
a non-Q wave myocardial infarction, and 2) to evaluate the 
effectiveness of thrombolytic therapy in patients presenting 
with ST segment depression and confirmed myocardial infarc- 
tion. 
Methods 
The methods and results of the LATE study (13) have been 
published. This trial was conducted in 230 centers from 13 
countries in men or women nlder than 18 years who had chest 
pain of >30 min duration attributed to suspected myocardial 
infarction. Eligible patients had ECG evidence of either ST 
elevation El mm in two or more limb leads or 22 mm in two 
or more chest leads, ST depression 22 mm in two or more 
leads, abnormal Q waves or abnormal T wave inversion in two 
or mom leads that was thought to represent a non-Q wave 
infarct. Patients without these changes, including those with an 
equivocal ECG or bundle branch block, who were found to 
have elevated serum cardiac enzyme levels, two or more times 
the normal level, were also included. Patients were treated 6 to 
24 h after the onset of chat pain according to the preriousiy 
descriid protocol. Patients with obvious contraindications to 
thromboiytii therapy (gastrointestinal or gastric ulcer bleeding 
witbinthepast6months,anyprevious stroke or history of 
transient ischemic attack in the past 6 months, neurosurgical 
trauma within the past 6 months, major surgery or trauma 
within the past month), shock with systolic blood pressure 
<80 mm Hg, hypertensbn (systolic pressure ZX!tl mm Hg or 
diastolii pressure =110 mm Hg) not controlled within the 6 to 
24-h window were excluded as were those who refused consent, 
were participating in another trial or had serious organic or 
psychiatricuhless. 
Patients were treated with either &PA (Genentech, Inc.) 
(1~rttg intravenous bolus, 50-mg intravenous infusion in 1 h, 
then 20 mg in each of the next 2 h) or matching placebo. In 
addition, they received immediate chewable or soluble aspirin 
foUawedbyadailydoseof75to360mgaccordingtothehtcal 
stitndard of prachce. fntravenous heparin was strongly advised 
for the 1st 48 h (according to the previously published proto- 
C& 46% of patients received heparin according to pmspeeihed 
pmto$ another 18% recefved heparin asadjunctive therapy 
a13yj local yyactiy and 36% recetved no adjuncthe 
Adrmm@atrou of ah other drugs and mterven- 
tied therapis was left to the discretion of the participating 
physickm with strong recommendation to use oral beta- 
adreriergic bIockitlg agents. 
greater with a designation as a Q wave or non-Q wave 
infarction and localization of infarction site (anterior, inferior, 
posterior) on the basis of assessment of the 12-lead ECG by 
principal site investigators before, hospital discharge. Possible 
myocardial infarction was defined by an increase in cardiac 
enzymes greater than normal but not reaching the twice 
normal level in the setting of an abnormal qualifying ECG. 
Measurement of serum creatine kinase [CK] was recom- 
mended for definition of myocardial infarction and was carried 
out in the majority of patients. 
St&is&al analysis. All results are reported as mean 
value + SD unless otherwise indicated. Comparison of base- 
line clinical characteristics was done by chi-square analysis or 
unpaired f test or by using analysis of variance and the Tukey 
test where appropriate. Cox model regression analysis was 
used to compare outcome between patients with Q wave and 
non-Q wave myocardial infarction and between patients re- 
ceiving rt-PA and placebo within subgroups of those present- 
ing with ST segment elevation, ST depression z-2 mm or 
neither. The covariates used in the Cox model regression 
analysis included the variables found to be unequal at baseline. 
Results 
Among 5,711 participants in the study, 4,759 had a con- 
firmed myocardial infarction, 3,450 (72.5%) were classified as 
having a Q wave myocardial infarction and 1,309 (27.5%) as 
having a non-Q wave infarction, with the remainder classified 
as having a possible infarction (558 patients), ischemic heart 
discase but no new proved infarction (263 patients) and chest 
pain of noncardiac or unknown cause (131 patients). 
The presenting 1Zlead ECG revealed ST segment eleva- 
tion or bundle branch block in 2,973 patients, ST depression 
22 mm in 528 patients and neither in 1,258 patients. 
Wvelopment of non-Q wave myocardial infarction in pa- 
tients treated with r&PA as compared to placebo occurred with 
equal frequency among patients presenting with ST segment 
elevation (189 of 1,401 [13.5%] vs. 202 of 1,428 [14.1%]), ST 
depression (128 of 259 [49.4%] vs. 151 of 291[51.9%]) or other 
presenting ECG criteria (327 of 694 [47.1%] vs. 312 of 686 
[45.5%]). 
Comparison of prognosis in non-Q wave and Q-wave 
myocnrdial htfmetiw (Table 1). Comparison of patients with 
Q wave and non-Q wave myocardial infarction revealed a 
greater proportion of patients with previous angina and previ- 
ous infarction among those with non-Q wave infarction. This 
group Blso had a slightly greater heart rate on admission and 
lower New York Heart Association functional class and were 
treated later (29.3% vs. 38.7% by <12 h, p = 0.0001). They 
also differed sigoh@ttly from the group with Q wave infarc- 
tion with respect to the adrniiion ECG: Fewer had ST 
segment elevation and more had either ST depression or lack 
of either ST elevation or ST depression on their admission 
ECG (i.e., T wave changes or other findmgs). 
Comparison of prognosis hreape&e of treatment assign- 
ment in &309 patients with non-Q wave myocardii infarction 
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Table I. Comparison of Patients With Q Wave and Non-Q Wave 
Myocardial Infarction 
Q Wave Non-Q Wave 
infarction Infarction 
(n = 3.450) (n = IJJY) 
Clinical characteristics 
Age (yr) 
Female 
Nonsmoker 
Hypertension 
Diabetes mellitur 
Hypercbolesterolemia 
Pmious angina 
Previous infarct 
Systolic blood pressure (mm Hg) 
Diastolic blood pressure (mm Hg) 
Heart rate (beat..min) 
NYHA class slf (5%) 
Killip cki.ss 2.7 (?) 
Time to treatment (h) 
Peak CK (IU/liter) 
Admission ECG 
=.t 
STI k2mm 
Q wave or T wave changes 
None of the ahove 
MI lmtion 
Anterior 
Nonanterior 
62.6 ? 10.X 
27 
35 
3s 
13 
20 
47 
16 
13X.6 + 24. I 
83.6 f 14.0 
78.9 2 17.5 
65.9 
20.6 
14.4 -r 5.1 
1.348i 1,34Y 
71 
8 
I6 
5 
42 
S8 
62.9 2 10.9 
26 
33 
36 
12 
21 
56’ 
29’ 
138.0 Z 24.0 
83.7 5 14.0 
80.0 x 18.0’ 
62.3’ 
2n.4 
15.7 2 5.4t 
961% 588t 
3n* 
21* 
26. 
23’ 
42 
5x 
‘p < 0.05. tp < O.owl. Data me presented as percent of @iints m mean 
value 2 SD. CK = creatine kin%; ECG = electrocardiogram: MI = mycwdial 
infarction: NYHA class = New York Heart Ass&&n functional class: ST 1 
and ST 1 = ST went elevation and ST segment depression, respectivety. 
versus 3.450 oatients with Q wave infarction revealed that the 
former had a’ lower mortal& rate at 35 days (7.6% vs. 115% 
RR = 0.62, 95% confidence interval [CI] 0.49 to 0.77, p = 
0.001) as well as at 1 year (13.3% vs. 17.1%, RR = 0.70,95% 
CI OS9 to 0.84, p = 0.001). The risk of reinfarction in patients 
with non-Q wave versus Q wave infarction was slightly lower at 
35 days (3.9% vs. S.l%, RR = 0.73,95% Cl 0.53 to 1.01, p = 
0.06) and similar at 1 year (8.6% vs. 7.9% p = 0.7). 
Of the 3,450 patients with Q wave myocardial infarction, 
1,710 were allocated to receive rt-PA and 1,740 !o receive 
placebo. No overall beneficial effect was seen in those given 
rt-PA versus placebo with respect to rate of mortality (11.2% 
vs. 11.7%) or reinfarction (5.3% vs. 4.910) at 35 days, or with 
respect to rate of mortality (16.9% vs. 17.3%) or reinfarction 
(8.2% vs. 7.6%) at 1 year (Fig. 1). As previously reported (13), 
the benefit from treatment with r&PA was seen only in those 
patients with Q wave myocardial infarckm who received 
treatment within 3 h of hospital admission (10.5% vs. 13.2%. 
p < 0.05). 
Prqm3.&innon-QartveBlgoeardiptiocsrctiw. Qf1.309 
patients with a confirmed diagnosis of definite non-Q wave 
myccardiil infarction, 644 were randmnkd to treatment with 
r&PA and 665 to placebo, the two groups were similar in 
haselii cliiical dlaracleristics induding time to IJxament 
Fffn 1. Comparison of cumulative I-year rates tif reinfarction (A) 
and survival (B) in patients with Q wave myocardial infarction (Ml). 
Patients treated with tt-PA (aolid limes) are compared with those 
treated with @aceho (dashed ks). No sign&cant difference %x, 
detected hehveen r&PA and placebo. 
(15.8 2 5.3 vs. 15.6 t 5.4 h) and peak creatine kinase (CK) 
(990 t 969 vs. 932 -C 794 W/liter, p = 0.24). There was no 
difference between patients receiving rt-PA or placebo with 
respect to in-hospital conmary artery bypass surgery (1.7% M 
1.7%, p = 0.9) or percutaneQus traasluminal corwary angio- 
plasty (2.3% vs. 2.9% p = 0.5). ‘ihere was also no difference 
between patients receiving r&PA or placebo in revasculariz8- 
tion rates at 1 year for coronary ansaoplasty (5.1% Vs S.9%, 
p = 056) or aorloc5nxury bypass surgery (8.4% vs. 9.5% p = 
0.49). 
The benefit conferred by admiistration of rt-PA,was 
evident at 35 days with lowering of the reirifarction rate (1.9% 
vs. 5.8%, RR = 033,95% CI 0.17 10 0.64, p = 0.0009) and 
decreased 35day morlality rate (5.4% vs, 9.61, RR = 0.57. 
95% Cl 0.3 to 0.86, p = 0.008). Moreover, the bea& extended 
to 1 year (Fig. 2) with lowering of the cumulative nzinfaretion 
rate (6.4% vs 10.8%, RR = 054.95% Cl 0.36 to 0.82. p = 
0.002) and mortality rate (10.6% M ML?%, RR = 0.66,95% 
cl 0.48 to 0.91, p = 0.004). 
Among patients with non-Q wave myocardii infarction. 
tbosetre.at&#afbxratherthaab&re12hfrtnnqmp@m 
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Table 2. Comparison of Patients According to 
Presenting Ektnxardiowam 
______ _____,__ _---- 
- 
*PA 
prrpne 2. Comparison of cumulative l-year rates of reinfaretion (A) 
and swival (B) in patients with non-Q wave myocardial infarction 
(Ml). Patients treated with &PA (solid lines) are compared with those 
treated with phcebo (ttasbi tines). Patients treated with CPA had a 
tower reinfaraion rate and deereased mortality (both p < 0.01). 
onset had similar benefit from &PA and placebo at 1 year with 
reapeutore~on(~l2b13of192vs.23of19o,p= 
0.w. >12 h 22 of 449 vs. 41 of 414, p = 0.014) or mortality 
(512 b 20 of 192 vs. 33 of 190, p = O.O5a, >12 h 43 of 449 vs. 
67 of 474, p = 0.029). 
In contrast to patients with Q wave myocardii infarction, 
treatment benefit in those with non4 wave infarction was 
similar amoog those treated with r&PA within 3 h of hospital 
admission (7.2% vs. 10.346, p c 0.05) as well as after 3 h (4.2% 
vs. 93%, p c 0.05). 
PmgnnsiiinpatlentsanalyEadbypreseatingECG.The 
clhdcal tAmmcteristics in patients with ST segment elevation, 
W depmskm or neither ST ekvation or depression are 
coqaredirtTabk2;patient+withSi,deprea+nwereolder 
andmotefrequentlyhadp&ousaoginaandmyocardial 
~~~~~~~~n~~~ 
ST eiemioa or neither ST elevation or ST depression. 
Among 2,973 patients presnting with ST elevatiou or 
bundle brad bloc& those who received &PA or placebo had 
a similar re&rction rate (4.9% vs. 5.1%, p = 0.7) and 
mortality rate at 35 days (11.3% vs. 12.7%, p = 0.2). Lack of 
~~~~~~~~~~~~ 
1yearforreinfarctkw(73%vs7.5%,p=O.9)andmortality 
Neither ST F 
srt STI amm UorsTl 
(II = L973) (Ii = 52s) (0 = 1,25s) 
Age 07) 63 2 11’ 65 +_ 10’7 aI+ I1 
Female 28 28 23 
Hx of hypertension 36 31 33 
Diabetes meltitus 14 12 11 
Hypercbolesterolemia 41 52 48 
Hx of smoking 63 66 70 
Previous angina 41 62’t 50 
Previous MI 16 xl’f 23 
NYHA class XII 23 3l’T 24 
*p < 0.05 versus neither ST 7 nor ST 1. tp < 0.05 versus ST t. Data are 
expressed as mean value + SD or percent of patients Hx = hiiory; other 
abbreviations as in Table 1. 
(21.2% vs. 22.4%, p = 0.5). The sample size available for this 
anaiysii allowed 90% power for detection of 20% relative 
reduction in mortality rate at 1 year. However, patients with 
these ECG characteristics who were treated with r&PA versus 
placebo <3 h after hospital admissiin had a decreased l-year 
mortality rate (15.8% vs. 19.6%, p = 0.028) in contrast to those 
treated >3 h after hospital admission (17.6% vs. 13.0%, p = 
0.055). 
Among 528 patients presenting with ST depression atone, 
those who received r&PA rather than placebo had a lower 
mortality rate (8.6% vs. 16.6%, p = 0.006) but not reinfarction 
rate (4.5% vs. 5.7%, p = 0.5) at 35 days. At 1 year they also had 
a lower mortality rate (20.1% vs. 31.9%, p = 0.006) but not 
reinfarction rate (7.8% vs. 10.3%, p = 0.3). 
No benefit from rt-PA was seen in 1,258 patients with 
neither ST elevation or ST depression with respect to rate of 
reinfarction (2.4% vs. 4.4%, p = 0.05) or mortality (4.7% vs. 
4.0%, p = 0.5) at 35 days or rate of reinfarction (5.5% vs. 6.6%, 
p = 0.4) or mortality (11.0% vs. lO.O%, p = 0.6) at 1 year. 
Prognusis in patients with pwsibk myocardial infardon. 
Among 558 patients classified as having possible myocardial 
infarction, 282 received t-t-PA and 276 received placebo. No 
difference was seen among those treated with &PA versus 
placebo with respect to rate of reinfarction (3.7% vs. 3.0%, p = 
0.64) or mortality (7.1% vs. 5.8%, p = 0.53) at 35 days or with 
respect to rate of reinfarction (9.7% vs. 10.2%, p = 0.82) or 
mortality (13.5% vs. 11.4%, p = 0.55) at 1 year. 
Discussion 
nKwvelfindingsofthis~~arethatl)whentherapyis 
adminktered late (>6 h after symptom onset) admiition 
of &PA rather than placebo improves long-term prognosis 
among patients who develop a non4 wave rather than a Q 
wave myxardkl infarction; and 2) thrombolytic therapy re- 
~~~~~~n~~~~ 
22mmandc4mhmedmyoeantiatinfardion. 
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Pmposislnnun-QwaveaadQwavemyocardialiohur- 
tIan. Our lindings demonstrate a prognostic benefit of throm- 
boiytic therapy versus placebo among patients who develop a 
non-Q wave myocardii infarction. The similar frequency of 
non-Q wave infarction among patients receiving It-PA and 
placebo, regardless of the presenting ECG, suggests that the 
administration of thrombolytic therapy did not increase the 
conversion of Q wave to non-Q wave myocardial infarction. 
Long-term benefit seen alter thrombolysii among patients with 
a non-Q wave infarction may be due to diminished likelihood 
of recurrent ischemia and reocchtsion, attenuation of ventric- 
ular dilation or enhanced electrical stability associated with 
improved late patency (14-16). A recently published second- 
ary analysis of the Thrombolysii in Myocardii Infarction 
(TIMI) II study (5) does not reveal the signiicantly greater 
reinfarction rate in non-Q wave versus Q wave infarction 
previously documented in the era before thrombolytic therapy 
(6-8). Recent analysis of data from the Global Utilization of 
Streptokinase and t-PA for Occluded Coronary Arteries 
(GUSTO) I study (17) also suggests a lower mortality rate in 
patients with a non-Q wave than in those with a Q wave 
infarction. 
Although patients were classified according to non-Q wave 
and Q wave myocardial infarction after study drug administra- 
tion, the end points of reinfarction and death used in this 
anaiysis were determined prospe&ely at 35 days and at 1 year 
and therefore provide a reliable measure of benefit observed in 
this double-blind placebo-controlled trial. The incidence of 
non-Q wave myocardial infarction was similar in our study 
(275%) and in the TIM1 II study (29.1%) (5). 
item?ut~~~mt~topresetst- 
lng KG. Our observations of thrombolytic benefit in patients 
presenting with ST depression appear to disagree with the 
results of GIN-I, ISIS-2 and TIMI-III (9-11); however, 
important dilfetences with respect to patient selection and 
underlying pathophysiology may have existed. In GISSI-I (9) 
and ISIS2 (10) only a small proportion of the overall sample 
(3.8% and 8%, respectively) presented with ST segment de- 
pression, and it is not clear how many of these patients bad 
confirmed myocardial infarction. In the TIMI-III study (11) 
1,473 patients with ischemic chest discomfort considered to 
represent unstable angina or non-Q wave infarction were 
randomized to treatment with r&PA or placebo. Only 32% of 
all patients had a non-Q wave infarction, and among those with 
cmdkmed myocardial infarction death and recurrent infarc- 
tioa occurred with similar frequency among patients who 
received r&PA or placebo. Of note, the TIMI-III study in- 
cluded a very low risk population with a 42day mortality and 
rehdarction rate of 2.4% sod 6.1%, respe&vely and was 
dhectedprimarhytowardpatientswithunstabRang@tbe 
dosert-PA(averrrge63mg)wasalsolowerthaotbatusedin 
the present study. 
In a recent ovetview of thrombolytic therapy, including 
GIN-I, ISIS2 and LKIE, the Fibrinoiytic Therapy Triahsts 
cdlaborative Group (1) exambxd short-term prognosis 
among4J37patientspresentingwith#myocm&u 
infarction without ST segment elevation. Those receiving 
thrombolysii had a 15.2% 35-c&y mortality rate compared with 
a 13.8% rate among placebotreated patients; however, the 
99% Cl ranged from a 12% reduction to a 44% increase in 
mortality. ‘Ihii pooled analysis included a heterogeneous pop 
ulation in whom cliiical suspicion and often minimal (<l-mm 
ST segment depression) or no ECG criteria were utilized in the 
decisiin to administer thrombolytic therapy. Thus, it is ahnost 
certain that many patients who received thrombolytic therapy 
in these trials did not actually have myocardial infarction sxd 
thus were unlikely to benefit from thrombolysii while beii 
exposed to the risk of this therapy. 
The diiculty in identifying which patients presenting with 
ST segment depression actuahy have an evolving acute myo- 
cardial infarction relates to the lower diagnostic predictive 
value of the ECG among patients without ST elevation. 
However, Lee et al. (12) nxently demonstrated that more 
prominent ST depression (22 mm) is highly specit? for the 
subsequent diagnosis of acute myocardii i&r&a. Fortu- 
itously, we had prospestively predefined ST depression ~2 mm 
as our admhsion criteria in the LATE study. We believe that 
this delinition, togther with con6wnation of myocardii in- 
farction, identified a pamfularty high risk group of patients 
who bendted from thmmboiytk therapy ia contrast to those 
studii in GISSI-I, ISIS-2 and TIMI-III. 
Lack of be&it among patients presenting with ST segment 
elevation suggests that the benefit usually associated with 
thrombolytii iLerapy was attenuated, perhaps because of its 
late admiitration (i.e., >6 h from symptom onset). A previ- 
ously reported pust hoc analysis (13) iadicated that patients in 
theLATEstudytreatedwi(hin3hofhaqrital2dmission,that 
ij those without undue delay in administration of thrombolytii 
therapy, experienced benefit. Similarly, we found that patients 
presenting with ST elevation who were treated <3 h after 
hospital adahioa derived beaeiit 
Patients without either ST segment elevation or ST depres- 
sion22mmonthepresentingECGhadnoevidexeofbenefit 
from thrombolytic therapy despite the poor pqnosis gener- 
allyobservedinthesepatientsEarlierd&nosiswithmore 
spedic markers of myocudii item&s may help to delineate 
asubgroupofsuchpatientsinwhom~maybe 
ben&zial. 
LimZtatianaol~sttttiy. Inaddiitotberenoqxtive 
natureofouranaly&andtheobviouscautionrequiredin 
interpr&ngourresuitswithrespect’totherapeutic~ill 
patients presenting with ST segment elevation or depreniocl 
otherliitationsofourstudyshouldbeconsidered.GXe 
iaborato~ and committeea for unifotm and sta&rdii 
interpretationofFXGswereno~tts&admimionanddi+ 
chargeECGsandevidenozofremfamthmwerelefttotbe 
d&cr&onofesperiencedprin@alinvest@orsatparti+it- 
ingcentem.Ahhoughw~centmlreadingmight 
haveinlIuencedtheoverallfre4prencyofsomeofour~ 
itwouldnothavebeenerrpxtedtoaltertbeirctbtrfbution 
between the tmatmentandpIacebognnrpsWewerenotable 
tofurtbers&cla&ythosepatienmwithoutSTsegmentele- 
vation or ST depression who had evidence of abnormal Q 
waves or T wave changes. Although these patients were more 
likely to be classified subsequently as having a non-Q wave 
rather than a Q wave myocardiai infarction, further separation 
of this group may have provided additional insight wkh respect 
to thrombolytii benefit in patients with myocardial infarction 
presenting without ST elevation or ST depression. 
ceedoshms. Patients destined to have a non-Q wave 
myocardial infarction constitute a heterogeneous group of 
patients whose admission ECG cannot be used reliably to 
identify the subsequent outcome of treatment or prognosis. 
Although the obr+vations presented here are limited to post 
hoc analysis, it is apparent that patients developing a non-Q 
wave infarction who receive thrombolytic therapy may have a 
better prognosis than those given placebo. Furthermore, 
thrombolytic treatment may be of benefit in patients present- 
ing with ST depression ~2 mm and confirmed myocardial 
infarction. These hypotheses require prospective testing in a 
large number of patients. 
We are extra&y gratefu! for the contniurions of the Starislical Department at 
Not@ham University, England. the technical assistance of Lois Adams. BSc 
and the editorial as&am-e of Linda Gray and Gail Karaim. 
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